Free Trial
→ A New Way to Double Your Retirement Income? (From Investors Alley) (Ad)tc pixel
NASDAQ:PROK

ProKidney Q2 2025 Earnings Report

ProKidney logo
$2.25 -0.05 (-2.17%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.30 +0.04 (+2.00%)
As of 09/5/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

ProKidney EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

ProKidney Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProKidney Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ProKidney's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

ProKidney's Q2 2025 Press ReleasePress Release
(8-K)
ProKidney's Q2 2025 Quarterly reportQuarterly report
(10-Q)

ProKidney Earnings Headlines

ProKidney Corp. (NASDAQ:PROK) Receives $6.25 Consensus Target Price from Brokerages
September 6 at 2:33 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30314086
Chronic Kidney Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
September 3, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34576894/chronic-kidney-disease-market-outlook-2034-clinical-trials-market-size-medication-prevalence-companies-by-delveinsight/
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
September 7 at 2:00 AM  |  Investors Alley (Ad)
ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript
September 3, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4819060-prokidney-corp-prok-presents-at-citis-biopharma-back-to-school-conference-transcript
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
August 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/27/3139909/0/en/prokidney-to-participate-in-two-upcoming-conferences-the-citi-biopharma-back-to-school-conference-and-the-morgan-stanley-global-healthcare-conference.html
ProKidney Reports 78 Percent Gain in Q2
August 14, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PROK/pressreleases/34096531/prokidney-reports-78-percent-gain-in-q2/
See More ProKidney Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email.

About ProKidney

ProKidney (NASDAQ:PROK), Inc. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products. These candidates are designed to mitigate inflammatory responses, promote tissue repair and reduce the progression of kidney damage in hospitalized patients at risk of AKI, including those undergoing major surgery or experiencing sepsis. In addition to its clinical-stage portfolio, the company maintains preclinical efforts exploring broader applications in CKD and related nephrology indications.

Founded in 2015 and headquartered in Massachusetts, ProKidney completed its initial public offering in 2022, trading on the NASDAQ under the ticker PROK. The management team comprises professionals with expertise in nephrology research, cell therapy manufacturing and clinical development. ProKidney conducts its clinical trials predominantly in the United States, collaborating with academic medical centers and specialized contract research organizations to advance its pipeline toward regulatory milestones.

View ProKidney Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles